Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-09-02
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Acarbose; Gliquidone; Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes

• No previous treatment for diabetes

• HbA1c: 7.0-12.0%

Exclusion Criteria:

• Type 1 diabetes

• Uncontrolled treated/untreated hypertension

• Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results

• Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures (adequate contraceptive measures are: sterilisation, intra-uterine device (IUD), oral contraceptives or barrier methods)